Premium
The Role of HIV Infectivity and Composition of Factor VIII Concentrates on the Immunity of Haemophiliacs Positive for HIV Antibodies
Author(s) -
Allain J.P.,
Frommel D.,
Bosser C.,
Gazengel C.,
Larrieu M.J.,
Sultan Y.
Publication year - 1987
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1987.tb04911.x
Subject(s) - medicine , titer , antibody , human immunodeficiency virus (hiv) , immunology , infectivity , immunity , immune system , antibody titer , platelet , gastroenterology , virus
. Forty‐six subjects (44 HIV antibody‐positive) with some degree of immune deficiency (at least TH/TS ratio below 1) were randomly distributed into 4 treatment groups. Each group was assigned to 1 of 4 products to be used exclusively for a 1‐year period: 1 concentrate was of intermediate purity and not heat‐treated, and 3 were heat‐treated in order to inactivate HIV, 2 of them being of higher purity. At 4–6‐month intervals, check‐ups, including as markers clinical examination, platelet, lymphocyte and T cell subset counts, IgG levels and delayed hypersensitivity test, were carried out. At entry as well as at the end of the study, groups were not statistically distinguishable. No intra‐ nor inter‐group differences were demonstrable for any of the markers. In contrast, using a scoring system for each marker and the results of check‐up at entry as reference, significant differences between groups appeared on subsequent check‐ups. Patients receiving intermediate‐purity factor VIII, whether heat‐treated or not, were mostly steady, while groups receiving heat‐treated concentrates of a higher purity significantly worsened. This surprising outcome was no related to differences in anti‐HIV titers or specificities. From this study, the potential long‐term predictive value of this scoring system could not be established.